Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 3:22 PM
Ignite Modification Date: 2025-12-24 @ 3:22 PM
NCT ID: NCT03479892
Eligibility Criteria: Inclusion Criteria: * Male aged 22-55 years (both inclusive) or female aged 22-45 years (both inclusive) at the time of signing informed consent * Female must have regular menstrual cycle(defined as 24-35 days between 1st day of menses for two most recent menstrual periods, self-reported) * Female must have bilateral tubal ligation or must be willing to use non-hormonal intrauterine device or diaphragm /cervical cap with spermicide in combination with condom for male partner(s) * Body mass index (BMI) between 27.0 and 39.9 kg/sqm (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator * Considered by the investigator to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG, and clinical laboratory tests performed during the screening visit Exclusion Criteria: * Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol * Use of prescription or non-prescription medicinal products including herbal products and non-routine vitamins, within 2 weeks prior to screening. Mild painkillers are allowed until 24 hours prior to screening * History or presence of bone disease or otherwise increased risk of bone fracture as evaluated by dual-energy x-ray absorptiometry and as judged by the investigator
Healthy Volunteers: False
Sex: ALL
Minimum Age: 22 Years
Maximum Age: 55 Years
Study: NCT03479892
Study Brief:
Protocol Section: NCT03479892